 Antibodies, Neutralizing
"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 2 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 2 | 4 | 6 | | 2012 | 4 | 3 | 7 | | 2013 | 2 | 3 | 5 | | 2014 | 4 | 2 | 6 | | 2015 | 2 | 6 | 8 | | 2016 | 3 | 5 | 8 | | 2017 | 7 | 5 | 12 | | 2018 | 6 | 5 | 11 | | 2019 | 3 | 6 | 9 | | 2020 | 9 | 7 | 16 | | 2021 | 15 | 22 | 37 | | 2022 | 3 | 25 | 28 | | 2023 | 1 | 10 | 11 | | 2024 | 2 | 7 | 9 | | 2025 | 13 | 13 | 26 | | 2026 | 4 | 4 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Stabell AC, Lee S, Park DJ, Lavine CL, Espinosa SM, Baharani VA, Patejak R, Nussenzweig MC, Caskey M, Seaman MS, Bieniasz PD, Hatziioannou T. Diverse paths to broadly neutralizing antibody escape among HIV-1 strains. Nat Microbiol. 2026 Jun; 11(6):1573-1584.
-
Acciani M, Zyla D, Niemeyer G, Harkins S, Parekh D, Pawlack E, Lacarbonara D, Kansara D, Ackerman ME, Niewiesk S, Porotto M, Hastie KM, Saphire EO. Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins. Cell Host Microbe. 2026 Jun 10; 34(6):1067-1081.e12.
-
Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.
-
Crofts KF, Holbrook BC, Page CL, Hendrix CJ, Caudell D, Gillespie RA, D'Agostino RB, Moin SM, Sangesland M, Ornelles DA, Kanekiyo M, Alexander-Miller MA. A dual-adjuvanted HA stem nanoparticle vaccine elicits a multifunctional antibody response that is associated with protection in newborn monkeys. Cell Rep Med. 2026 May 19; 7(5):102746.
-
Zyla DS, Della Marca R, Lacarbonara D, Niemeyer G, Zipursky G, Di Clemente L, Verbruggen MHL, van Dijk LLA, Ceh OM, Jonathan-Trakht G, Kalantarov G, Acciani M, Laterza G, Vyshenska D, Leedale C, Pawlack E, Hastie KM, Horvat B, de Swart RL, de Vries RD, Greninger AL, Niewiesk S, Ollmann Saphire E, Porotto M. Structural and mechanistic basis for antibody neutralization of the measles fusion protein. Nat Commun. 2026 Apr 06; 17(1).
-
Silva MVM, Ximenes RAA, Filho DBM, Martelli CMT, de Araújo TVB, Brickley E, Fontes JMSSA, Fulco GRN, Sá ACCL, Cordeiro MT, Castanha PMDS, Dos Santos Oliveira PA, Montarroyos UR. Kinetics of neutralizing and binding antibody responses following Zika virus infection during pregnancy: A nested analysis of participants from the microcephaly epidemic research group (MERG) and Zika in infants and pregnancy (ZIP) cohorts. Virus Res. 2026 Jun; 368:199725.
-
Zoref-Lorenz A, Allen CE, Behrens EM, Chandrakasan S, Chien M, Hermiston ML, Hinson AP, Intzes S, Isakoff MS, Leiding JW, Oladapo A, Panigrahi A, Patel SA, Pednekar P, Ray AK, Rothman JA, Saldaña BD, Walkovich KJ, Weinstein J, Yee JD, Jordan MB, Weinstein J, Hinson AP, Allen CE, Eckstein OS, Gulati N, Chandrakasan S, Haines H, Nakano TA, Patel SA, Behrens EM, Intzes S, Hays A, Saldaña BD, Jordan MB, Zoref-Lorenz A, Hanna R, Isakoff M, Ray AK, Rothman JA, Tandra A, Cooper R, Leiding JW, Chien M, Sarangi S, Gidvani-Diaz VK, Satwani P, Carter J, Henry M, Gloude N, Bhatt S, Bhatla D, Draper L, Panigrahi A, Hermiston ML, Modica R, Riskalla M, Baker A, Ward B. Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.
-
Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, Yin DE, Moye J, Spiegel H, Gama L, Gaudinski M, Capparelli EV. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. J Antimicrob Chemother. 2026 Jan 19; 81(2).
-
Muthuraman K, Jackman M, Liang Y, Garrett ME, Cui H, Nguyen LVH, Ivanochko D, Ye C, Pino PA, Hicks A, Maingot B, Yusko E, Benzeno S, Martínez-Sobrido L, Torrelles JB, Gilbert AE, Rubin BER, Keitany G, Jetha A, Julien J-P. Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions. J Virol. 2025 12 23; 99(12):e0152325.
-
Ho AWS, Fukuzawa T, Koga H, Ohmine K, Kawauchi H, Muraoka M, Ikuta Y, Gupta G, Okuda M, Onami I, Ayabe M, Takeiri A, Konishi H, Sugawara Y, Usami S, Ito E, Shibahara N, Ozeki K, Wada Y, Hirako A, Takahashi N, Sampei Z, Haraya K, Murao N, Fujii T, Torizawa T, Shimada H, Igawa T. Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function. EBioMedicine. 2025 Dec; 122:106009.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|